Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-07-20

Clinical Trial Results: A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease [Phase 3]

View source ↗

Summary

Phase 3 trial results for once-daily oral orforglipron (LY3502970) in Japanese adults with obesity have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Orforglipron (orforglipron)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity | Phase 3 | Status: COMPLETED | Results posted: 2026-07-20